DelveInsight’s “Hypoparathyroidism Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hypoparathyroidism market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Hypoparathyroidism drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Hypoparathyroidism treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Hypoparathyroidism: An Overview
Hypoparathyroidism is characterized by hypocalcemia and hyperphosphatemia due to a lack of parathyroid hormone (PTH) secretion or action. Hypoparathyroidism may occur as part of a pluriglandular autoimmune disorder or as a complex congenital defect, for example in the autosomal dominant DiGeorge or hypoparathyroidism, deafness, and renal dysplasia (HDR) syndromes.
Due to a deficiency of the parathyroid hormone, individuals may exhibit abnormally low levels of calcium in the blood (hypocalcemia) and high levels of phosphorus (hyperphosphatemia). The most common cause of the disease is injury or removal of all 4 parathyroid glands. That can accidentally happen during surgery to remove the thyroid. Some people are born without these glands. And in some cases, the glands do not work well for unknown reasons.
Hypoparathyroidism Market Key Facts
The current Hypoparathyroidism therapeutic landscape in the 7MM is driven by several approved therapies, including those with off-labeled products.
Natpara (parathyroid hormone/rhPTH [1-84]) is the one and only approved drug for the treatment of hypoparathyroidism, which is approved in the US as well as in Europe.
Of all the Hypoparathyroidism therapies in the 7MM, the majority of the market share is accommodated by TransCon PTH, which is expected to generate USD 1,342 million in 2032.
The total Hypoparathyroidism prevalent population in the 7MM ranges from 280,275 in 2021, growing at a CAGR of 1.23% during the study period [2019–2032].
The total diagnosed prevalent population of hypoparathyroidism in the United States ranges from 81,320 in 2021, growing at a CAGR of 1.50% during the study period [2019–2032].
Among the European five countries, the United Kingdom had the highest prevalent population of hypoparathyroidism with 34,569 cases, followed by Germany and France in 2021. On the other hand, Spain had the lowest prevalent population.
Japan had 22,310 prevalent cases of hypoparathyroidism in 2021.
As per DelveInsight’s analysis, a higher percentage of Hypoparathyroidism prevalence was observed for females, in comparison to males, in all the 7MM countries.
According to DelveInsight’s analysis, it has been observed that hypoparathyroidism prevalence varied across the 7MM countries, based on the age-specific prevalence of the disease. For instance, the highest proportion was observed in the 65+ Years age group in the US, while in the EU-5 countries, people aged 55-64 Years accounted for the maximum patient pool.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Hypoparathyroidism pipeline therapies. It also thoroughly assesses the Hypoparathyroidism market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Hypoparathyroidism drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Hypoparathyroidism Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Hypoparathyroidism epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Hypoparathyroidism epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Hypoparathyroidism Epidemiology, Segmented as –
Prevalent Cases of Hypoparathyroidism in the 7MM [2019–2032]
Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the 7MM [2019–2032]
Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the 7MM [2019–2032]
Diagnosed Prevalent Cases of Hypoparathyroidism in the 7MM [2019–2032]
Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the 7MM [2019–2032]
Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the 7MM [2019–2032]
Hypoparathyroidism Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Hypoparathyroidism market or expected to be launched during the study period. The analysis covers the Hypoparathyroidism market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Hypoparathyroidism drugs based on their sale and market share.
The report also covers the Hypoparathyroidism pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Hypoparathyroidism companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Hypoparathyroidism Market Will Evolve and Grow by 2032 @
Hypoparathyroidism Therapeutics Analysis
The dynamics of the Hypoparathyroidism market are anticipated to change during the forecasted period owing to the expected launch of emerging therapies. Many pipeline therapies are under development for the prevention and treatment of hypoparathyroidism. Some of the key therapies under development for the treatment of hypoparathyroidism include TransCon PTH (Ascendis Pharma), EnteraBio (EB612), Encaleret (Bridgebio/Calcilytix Therapeutics). Currently, Ascendis Pharma is leading the therapeutics market with its Hypoparathyroidism drug candidates in the most advanced stage of clinical development.
Hypoparathyroidism Companies Actively Working in the Therapeutics Market Include
AEterna Zentaris Inc
And many others
Emerging and Marketed Hypoparathyroidism Therapies Covered in the Report Include:
Encaleret (BBP-305/CLTX-305): Bridgebio/Calcilytix Therapeutics
TransCon PTH: Ascendis Pharma
And many more
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Hypoparathyroidism Competitive Intelligence Analysis
4. Hypoparathyroidism Market Overview at a Glance
5. Hypoparathyroidism Disease Background and Overview
6. Hypoparathyroidism Patient Journey
7. Hypoparathyroidism Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Hypoparathyroidism Treatment Algorithm, Current Treatment, and Medical Practices
9. Hypoparathyroidism Unmet Needs
10. Key Endpoints of Hypoparathyroidism Treatment
11. Hypoparathyroidism Marketed Therapies
12. Hypoparathyroidism Emerging Drugs and Latest Therapeutic Advances
13. Hypoparathyroidism Seven Major Market Analysis
14. Attribute Analysis
15. Hypoparathyroidism Market Outlook (In US, EU5, and Japan)
16. Hypoparathyroidism Companies Active in the Market
17. Hypoparathyroidism Access and Reimbursement Overview
18. KOL Views on the Hypoparathyroidism Market
19. Hypoparathyroidism Market Drivers
20. Hypoparathyroidism Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
DelveInsight’s specialized oncology consulting empowers the pharma and biotech giants with tailored guidance and forefront proficiency, enabling adept navigation of ever-evolving clinical, commercial, and regulatory landscapes. Explore further at @ Oncology Consulting Services
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States